Long-acting Paliperidone Palmitate - Interim Results of an Observational Study of Its Effect on Hospitalization

Overview

Journal Int Clin Psychopharmacol

Specialty Pharmacology

Date 2014 Jan 15

PMID 24419004

Citations 22

Authors

David Taylor

Olubanke Olofinjana

Affiliations

Soon will be listed here.

Abstract

Paliperidone palmitate (PP) is a recently introduced long-acting atypical, or second-generation, antipsychotic. Published data on PP are currently limited to controlled trials and case reports. In this observational study, we followed up 200 consecutive patients prescribed PP in normal practice. After 1 year, 65% of patients were still receiving PP. The number of admissions to hospital in the year following PP initiation was 0.49/patient compared with 0.69/patient/year, 3 years before initiation (P=0.0001). The mean number of bed days fell from 38.78 to 23.09/patient/year over the corresponding period (P=0.0001). The median number of bed days 3 years before PP initiation was 21.50/year and in the year following PP initiation, it was 0. Outcomes were numerically but not statistically better in those continuing PP than in those who ceased PP within a year of initiation. PP was effective and well-tolerated and, given its positive effect on hospital bed days, broadly cost-effective.

Citing Articles

Health economics study of paliperidone palmitate in the treatment of schizophrenia: a 12-month cohort study.

Luo X, Liu F, Lu J, Cheng Y, Xu X, He X BMC Psychiatry. 2024; 24(1):439.

PMID: 38867159 PMC: 11167766. DOI: 10.1186/s12888-024-05874-1.

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium.

Cai R, Decuypere F, Chevalier P, Desseilles M, Lambert M, Fakra E BMC Psychiatry. 2022; 22(1):382.

PMID: 35672743 PMC: 9171957. DOI: 10.1186/s12888-022-03914-2.

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses.

Kadra-Scalzo G, Ahn D, Bird A, Broadbent M, Chang C, Pritchard M BMJ Open. 2022; 12(4):e051567.

PMID: 35387806 PMC: 8987753. DOI: 10.1136/bmjopen-2021-051567.

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate.

Mason K, Barnett J, Pappa S Ther Adv Psychopharmacol. 2021; 11:20451253211029490.

PMID: 34349980 PMC: 8295959. DOI: 10.1177/20451253211029490.

Relapse and frequency of injection of monthly paliperidone palmitate-A retrospective case-control study.

Laing E, Taylor D Eur Psychiatry. 2021; 64(1):e11.

PMID: 33531095 PMC: 8057373. DOI: 10.1192/j.eurpsy.2021.4.

References

Castberg I, Spigset O . Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit. 2005; 27(1):103-6. DOI: 10.1097/00007691-200502000-00019. View

Taylor D, Young C, Patel M . Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol. 2006; 9(6):685-94. DOI: 10.1017/S1461145705006309. View

Novick D, Haro J, Bertsch J, Haddad P . Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010; 30(5):531-40. DOI: 10.1097/JCP.0b013e3181f14098. View

Tiihonen J, Haukka J, Taylor M, Haddad P, Patel M, Korhonen P . A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168(6):603-9. DOI: 10.1176/appi.ajp.2011.10081224. View

Young C, Taylor D . Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand. 2006; 114(1):14-20. DOI: 10.1111/j.1600-0447.2006.00766.x. View

Rubio G, Martinez I, Ponce G, Jimenez-Arriero M, Lopez-Munoz F, Alamo C . Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006; 51(8):531-9. DOI: 10.1177/070674370605100808. View

Bowskill S, Handley S, Fisher D, Flanagan R, Patel M . Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010. Ther Drug Monit. 2012; 34(3):349-55. DOI: 10.1097/FTD.0b013e3182577c43. View

Taylor M, Currie A, Lloyd K, Price M, Peperell K . Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol. 2008; 22(2):128-31. DOI: 10.1177/0269881107084068. View

Leucht S, Pitschel-Walz G, Abraham D, Kissling W . Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35(1):51-68. DOI: 10.1016/s0920-9964(98)00105-4. View

10.

Rosenheck R, Krystal J, Lew R, Barnett P, Fiore L, Valley D . Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011; 364(9):842-51. DOI: 10.1056/NEJMoa1005987. View

11.

Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V . Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry. 2008; 70(2):196-200. View

12.

Hogarty G, Schooler N, Ulrich R, Mussare F, Ferro P, Herron E . Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979; 36(12):1283-94. DOI: 10.1001/archpsyc.1979.01780120013001. View

13.

Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V . Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand. 2009; 120(2):97-101. DOI: 10.1111/j.1600-0447.2009.01352.x. View

14.

Niaz O, Haddad P . Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007; 116(1):36-46. DOI: 10.1111/j.1600-0447.2006.00980.x. View